The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | A study investigating the efficacy of CAR-T therapy in Richter’s transformation
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses a study on CAR-T in patients with Richter’s transformation. The study found that 65% of the 54 patients treated with CAR T-cell therapy responded well, with about 50% achieving complete responses and a progression-free survival (PFS) exceeding two years. This highlights the need for more controlled studies to seek approval for CAR-T as a treatment option for this difficult-to-treat population. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche; Consultancy: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche; Honoraria: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche.
